Hepatic xenotransplantation: Clinical experience by Marino, IR et al.
, 
j 
I 
Nicolo Bassi 
Associatc Profcssor of Surgery 
Ullil'£'Tsitlf of Padol'n, 
Chicf IV Dcpartlilcllt of Surgery 
Trcviso Civic Hospital, Trcl'iso, Italy 
Davide F. D'Amico 
Professor of Surgery 
Director, 1I1stitutc ofCiinica Chirurgica I 
and Livcr Transplant Program 
Univcrsity of Padova, Italy 
Umberto Tedeschi 
Assistant Professor of Surgery 
Institute of Ciillica Chirurgica I 
mId Lil'er Trmlsplmlt Program 
University of Padol'n, Italy 
Umberto Cillo 
Sta/fLil'er Transplallt SIIrge011 
1I1stitute of Ciinica Cllirurgica I 
and Liller Trmlsplmzt Program 
University of Padol'n, Italy 
Liver 
Transplantation 
Procedures and Management 
PREFACE 
Thomas E. Starzl M.D. Ph.D. 
Professor of Surgery 
Director, Transplantation Institute 
University of Pittsburgh Medical Center 
University 
of Pad ova 
University of Pittsburgh 
Medical Center 
MASSON IBTI 
Milano. Parigi • Barcellona 
1994 
22 
Hepatic Xenotransplantation: 
Clinical Experience 
I.R. Marino, A.G. Tzakis, J.J. Fung, S. Todo, H.R. Doyle, T.E. Starzl 
HISTORICAL BACKGROUND AND RATIONALE 
The concept of a xenotransplant (transplantation 
of cells, tissue and organs between different species 
to create a chimera) is so old that it can be found in 
Greek and Roman classical mythology. Homer, in 
describing the centaur Chiron [1], master of Aescula-
pius, and the Chimera [2] was actually proposing 
two mythological examples of discordant xenogenic 
creatures [3]. However, it was only during the early 
part of this century that a scientific approach was 
adopted, both experimentally and clinically [4-9], to 
the question of xenotransplantation. The first at-
tempts were totally unsuccessful, basically because 
knowledge of pathophysiology, immunology, and 
even vascular surgical procedures was very prim-
itive 60 to 90 years ago, when compared to what we 
know now. Consequently, the initial reports of suc-
cessful (or at least partially successful) clinical xe-
notransplants date back to the 1960's [10-13]. The or-
gan most frequently involved during these early 
clinical trials was the kidney. Dialysis was not yet an 
available therapy, and patients with terminal kidney 
failure were destined to die from uraemia. In con-
trast to the liver, kidney transplantation was already 
well defined from a technical point of view, and a 
number of successes had been achieved in clinical al-
lotransplantation using immunosuppression based 
on antimetabolites and steroids [14-19]. The crisis 
brought about by the lack of donor organs led to 
these early clinical attempts, as xenotransplantation 
seemed to be the only operation which could be of-
fered on a large scale to patients with terminally dis-
eased organs. The results achieved by Keith Reemt-
sma [10] and Thomas Starzl [12] were very encourag-
ing, with patients surviving without dialysis for sev-
eral months (2 months in the experience of Starzl 
and up to 9 months for Reemtsma). In 1965, how-
ever, dialysis became possible in both Reemtsma's 
and Starzl's hospitals, and this was accompanied by 
a simultaneous increase in the number of donor or-
gans available. These two factors lead to the suspen-
sion of clinical kidney xenotransplant programs. 
Clinical xenotransplants of the heart and liver 
were occasionally attempted, without success, over 
the next 20 years [20]. Meanwhile, the refinements of 
surgical techniques and, above all, the introduction 
of Cyclosporine into clinical use by Sir Roy CaIne 
[19,21] created a second organ shortage crisis in the 
1980's. In 1984 Leonard Bailev, of Lorna Linda, raised 
the hopes of the scientific· community when he 
transplanted a baboon's heart into a newborn baby 
weighing 2.6 kg, known as Baby Fae [22]. However, 
the immunosuppressants used (steroids, Cyclospo-
rine, azathioprine and antithymocyte globulin) were 
not sufficient to control humoral rejection. 
Humoral rejection had actually already been rec-
ognized as far back as 1965 as the principal immu-
nological barrier to xenotransplantation [3, 12, 13, 20, 
23,24]. Different procedures for preventing and con-
trolling humoral rejection, both in allo- and xe-
notransplantation, have been studied since then, 
many of which have already been discussed by our-
selves and others [25-30]. Among the various meth-
ods used in the past, two drugs in particular have re-
cently attracted our attention: prostaglandin E1 and 
cyclophosphamide. 
Treatment with prostaglandins has been shown to 
be useful in mitigating pathophysiological events 
linked to humoral rejection in various experimental 
xenotransplant protocols [27, 31-34]. Furthermore, 
Quagliata et a1. had already demonstrated in 1972 
that prostaglandin E has a direct action on the activ-
ity of B lymphocytes [34]. Although the liver is tradi-
tionally considered to be resistant to humoral rejec-
tion [35], there are several examples of antibody in-
duced rejection of liver allotransplants in the clinical 
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literature [36]. For this reason, we added prostaglan-
din E1 to our immunosuppressant protocol for liver 
allotransplants in 1992, and this allowed us to 
achieve the same survival results in positive cross-
match patients as in negative cross-match ones [37]. 
Cyclophosphamide is an alkylating agent that 
blocks the cell c~Dcle in the G2 phase, and has been 
widelv used in cancer chemotherapy [38]. It is also a 
powerful immunosuppressant [19] that acts on the 
humoral [39] and cellular [40-42] limbs of the im-
mune response, being capable of reversing rejection, 
both experimentally [43-50] and clinically [46,51-55]. 
Early successful experience in clinical bone marrow 
transplantation [56], as well as in a limited number 
of kidney transplants [57, 58], encouraged its use in a 
larger series of solid organ transplants, in combina-
tion with prednisone and anti-lymphocyte immu-
noglobulins [51, 55] or, in some cases, azathioprine 
[51-54]. 
More recentl\', Murase et al. achieved 100';'0 long-
term survival i"n a hamster to rat heart xenotrans-
plant modeL using a combination of FK506 and cy-
clophosphamide [59]. The success obtained in this 
modeL combined with the clinical experience ac-
crued during the Sixties, provided the rationale for a 
new clinical xenotransplant trial at the Pittsburgh 
Transplantation Institute in 1992. Although the 
chimpanzee is most likely the best donor in biolo-
gical terms, due to the very small genetic differen-
ces between them and humans, their endangered 
status prevents their widespread use for scientific 
purposes. In the United States, only 25-50 chimpan-
zees may be used annually in biomedical research, 
including those used in AIDS research [60], and it is 
estimated that only 70 chimpanzees would be avail-
able worldwide as organ donors each year [61]. 
Therefore, it was decided that the donor would be 
the baboon (Papio cynocephalus), and the organ cho-
sen for this initial clinical trial was the liver, on ac-
count of its resistance to humoral rejection [35-37, 
62-65]. The pharmacological cocktail used for pre-
venting and controlling rejection was a combination 
of "old" (steroids, cyclophosphamide and pros-
taglandin E1) [19] and "new" (FK506) [66] immuno-
suppressant drugs. 
DONOR SELECTION 
The baboons used as donors came from the South-
west Foundation for Research and Education, San 
Antonio, Texas, the same institution that supplied 
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the baboons used in the previous kidney xenotrans-
plant trial [12]. All the baboons used d'uring donor 
selection were Papio cylloccplwlllS, and v,'ere born in 
the US [67]. 
Baboons have group A, Band AB antigens weakly 
expressed in all cells, with group a baboons being ex-
tremely rare [68]. However, ABO incompatibility did 
not affect the results of previous clinical xenotrans-
plant trials [12, 18]. An ABO match is desirable in a 
baboon-to-human xenotransplant. but its absence 
does not constitute an absolute contraindication. Ta-
ble 22.1 shows the blood groups of both donors and 
recipients. Both patients, blood group A and B, re-
spectively, received their liver from compatible do-
nors. In addition to blood group, donor selection cri-
teria included a lymphocytotoxic cross-match, as 
well as a complete biochemical, viral and bacteri-
ological evaluation of the animals [69J. In particular, 
infectious disease screening was performed at the 
Virus Reference Laboratorv of the Southwest Foun-
dation for Research and 'Education, San Antonio, 
Texas. All potential donors were screened for retro-
viruses (STLV, HTLV, SlY, SRY-l, SRY-2, SRY-5, HY-J, 
HIY-2 and Foamy virus), Herpes viruses (SA-S, HSY, 
B-virus, rCMY, hCMY, EBY and YZY) and hepatitis 
viruses (HBY, HAY, and HCY). In addition to this, 
the animals were examined to exclude tuberculosis 
and toxoplasmosis, and routine cultures of blood 
and faeces were performed. 
DONOR OPERATION 
The donor operation was performed using the tra-
ditional technique described by our group [70]. The 
operations on the donor and the recipient were per-
formed simultaneously, in two different operating 
theaters. Cold ischemia times were 80 minutes in the 
first case and 231 minutes in the second. University 
of Wisconsin solution was used to preserve the or-
gans, as is done in our routine clinical practice. 
RECIPIENT OPERATION 
The liver xenotransplant was performed using a 
modification of our standard method, described 30 
years ago [71], and employing veno-venous by-pass 
[72]. The difference in diameter between the vessels 
of both donor and recipient, and the small size of the 
Tab. 22.1. Blood groups and demographical data of the first 2 cases of baboon-to-human liver transplantation. 
Blood group C) Age/sex Diagnosis Previous surgery Xenotransplant date Survival (days) 
A 3S/maie Hepatitis B Splenectomy 6128192 70 
2 B 621male Hepatitis B 1/10/93 26 
(') Donor and recipient were of the same blood group. 
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Fig. 22.1. Case 2. 
Cholangiogram performed on post-operative day 18. by in-
jection through the percutaneous biliary catheter. This cathe-
ter was placed during the xenotransplant operation across 
the choledochojejunostomy (arrow). and allowed study of the 
biliary anatomy. as well as daily collection of bile samples af-
ter the xenotransplant. 
donor's liver (600 cm' and 450 cm' in the first and the 
second cases, respectively) made it necessary to use 
the piggy-back method [73]. In both cases the right 
suprahepatic vein of the recipient was closed with a 
running suture, whilst the left and middle suprahe-
patic veins were used to perform the suprahepatic 
vena cava anastomosis. The donor's celiac axis was 
anastomosed end-to-end onto the recipient's com-
mon hepatic artery in the first case, and end-to-side 
onto the supra celiac aorta, using a carotid artery in-
terposition graft, in the second. 
In the first case, given the considerable dis-
crepancy between the recipient and donor portal 
veins, the latter was anastomosed end-to-end onto 
the recipient's left portal branch, and the right 
branch was closed with a running suture. In the sec-
ond case, the smaller discrepancy made it possible to 
perform a normal end-to-end portal anastomosis. In 
both cases, the liver reperfused uniformly and pro-
duced bile on the operating table. The biliary anasto-
mosis was done using a choledochojejunostomy on 
a Roux loop. In the second case, a small (3.5 F) diam-
eter catheter was placed into the biliary anastomosis 
and brought out through the abdominal wall (Fig. 
22.1), in order to gain direct access to the bile duct, to 
study its anatomy and take bile samples during the 
post-operative period. 
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IMMUNOSUPPRESSIVE THERAPY 
The immunosuppressive protocol comprised 4 
drugs: cyclophosphamide, FK506, methylpredniso-
lone and prostaglandin EJ • The cyclophosphamide 
was started 2 davs prior to the transplant, and ad-
ministered for a total of 56 days in the first case and 
10 days in the second, at a dosage varying between 
0.07 and 10.6 mg/kg/day. FK506, steroids, and pros-
taglandin were started on the day of the transplant, 
using the same protocol we follow in clinical liver al-
lotransplantation. A detailed description of the im-
munosuppressive drug dosing, and blood levels ob-
tained, was recently published [74, 75]. 
CLINICAL COURSE 
As of this writing, there have been 2 clinical ba-
boon liver xenotransplants, performed on June 28, 
1992, and January 10, 1993, respectively. The first pa-
tient was extubated 17 hours after the operation, and 
he lived for 70 days mostly in a regular hospital 
ward, with a relatively normal quality of life. The 
second patient, who was much older (see table 22.1), 
never regained a level of consciousness sufficient to 
allow him to be weaned off the mechanical ventila-
tor, and survived for only 26 days. Figures 22.2 and 
22.3 describe the post-operative courses, as pertains 
to the transplanted liver function. 
The first patient underwent 5 liver biopsies, while 
the second had 7. None of the biopsies showed 
acute cellular rejection, according to the criteria rou-
tinely used in liver allotransplantation [74-76]. How-
ever, direct immunofluorescence demonstrated the 
presence of endothelial deposits of immunoglobu-
lins (IgG>IgA>IgM), and complement (particularly 
Clq) in both cases. 
Macroscopically, considerable hepatic regenera-
tion was noted in both cases, with a significant in-
crease in the volume of the baboon organs. Figure 
22.4 shows the organ transplanted into the first pa-
tient, during the course of an open liver biopsy per-
formed on July 10, 1992, 12 days after the xenotran-
splant. The normal multilobar appearance of the ba-
boon liver is evident, as is the increase in volume 
when compared with its original size (600 cm3). 
Computerized tomography was used to calculate the 
volume of the transplanted livers [77]. Both livers 
showed an extremely rapid volumetric growth, as 
normally occurs when a human liver is transplanted 
into a recipient with a larger abdomen than the do-
nor [78]. Figures 22.5 and 22.6 show the compute-
rized tomographies performed on the two recipients, 
on the 26th and the 14th post-operative days, respec-
tively. The first patient's liver grew from an initial 
volume of 600 em3 to 1,555 cm3 in 26 days. The sec-
ond patient's liver grew from an initial volume of 450 
cm3 to 1,741 em3 in 14 days. 
As mentioned above, cellular rejection was not a 
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tal bilirubin values during the post-operative course. Bx shows the number of liver biopsies. and the days when they were 
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Fig. 22.3. Case 2. 
The graph shows alanine-aminotransferase (ALT), aspartate-aminotransferase (AST), alkaline phosphatase (Alk. Ph.), and to-
tal bilirubin values during the post-operative course. Bx shows the number of liver biopsies, and the days when they were 
performed. 
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Fig. 22.4. Case 1. 
Intraoperative photograph taken 12 days 
after the xenotransplant. when the patient 
was explored to perform an open liver 
biopsy. The normal multilobar anatomy of 
the baboon liver is clearly appreciated. 
Fig. 22.S. Case 1. 
Abdominal CT on post-operative day 26. 
The liver volume has increased to 1.555 
cm3, from an initial value of 600 cm3• 
problem with either patient. The pharmacological 
cocktail used (cyclophosphamide, FK506, methyl-
prednisolone and prostaglandin E1) prevented the 
immunological lesions characteristic of xenotrans-
plantation [20]. 
The effectiveness of these drugs in the experi-
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mental concordant xenotransplant [59, 79] was also 
confirmed in our clinical experience. The cause of 
death in the first patient was a subarachnoid hemor-
rhage, caused by angioinvasive aspergillosis. 
The second patient's death was due to bacterial 
sepsis. 
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ANALYSIS OF RESULTS 
THE CHOLESTASIS ENIGMA 
From an immunopathological point of view, we 
paid particular attention to the presence of T lym-
phocytes (CD4+ < CD8+) and NK cells in the basal 
membrane of the biliarv canalicula. This is due to the 
fact that both patients'showed definite signs of in-
trahepatic cholestasis with a virtually intact hepato-
cellular architecture. As can be seen in Figure 22.2, 
the first patient had a normal serum bilirubin for 
much of the post-operative course, whereas the alka-
line phosphatase was always very high. Alkaline 
phosphatase values in the second patient were not 
as conspicuously high as in the first (Fig. 22.3), al-
though they were always above normal limits. Se-
rum bilirubin in the second patient never reached a 
normal value, remaining above 8 mg/dL. Whereas 
the post-mortem examination revealed the presence 
of a large amount of biliary sludge in the first pa-
tient, possibly linked to an obstructive problem, the 
transanastomotic biliary catheter in the second pa-
tient excluded mechanical factors as the aetiology of 
the increase in canalicular enzymes. 
BIOLOGICAL DIFFERENCE 
The two cases were basicallv different from an im-
munological viewpoint. The first patient had a sple-
nectomy in 1989 following a motorcycle accident, 
whereas the second patient still had his spleen, 
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Fig. 22.6. Case 2. 
Abdominal CT on post-operative day 14. 
The liver volume has increased to 1.741 
cm3• from an initial value of 450 cm3. 
which was subsequently removed 4 days after the 
xenotransplant. The first patient was also HIV-
positive. Although he was considered immunocom-
petent at the time of the transplant, and had no 
changes in this state during his post-operative 
course [74], it is difficult to judge whether his condi-
tion provided a natural immunosuppression, and 
whether or not this represented an advantage. Our 
centre traditionally does not refuse transplantation 
to HIV-positive subjects [80], but analvsis of the im-
munological parameters obviously differs in the case 
of an allotransplant. After completing the vascular 
anastomoses the second patient was given an in-
fusion of bone marrow cells from the donor baboon. 
This was aimed at increasing the natural tolerogenic-
ity induced by the liver transplant [81]. It is believed 
the liver has certain advantages in immunological 
terms on account of the large number of dendritic 
cells it possesses. These cells abandon the trans-
planted organ and participate in a two-way cell traf-
fic, which gives rise to micro chimerism [82, 83] (see 
also Chapter 25). The autopsy on the first patient 
confirmed these expectations, since baboon DNA 
was found in the patient's heart, kidneys, lungs and 
lymph nodes. All blood samples taken from the sec-
ond patient during the post-operative course 
showed the presence of xenogeneic DNA. 
METABOLISM 
In addition to immunological problems, clinical 
liver xenotransplant also has important metabolic as-
pects. A baboon liver transplanted into a human 
continues to produce the donor's phenotypical pro-
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teins. This concept is the basis on which many con-
genital metabolic abnormalities are solved by al-
lotransplantation of the liver [84, 85]. It follows th(lt 
liver xenotranspl(lnt creates a baboon-specific hepat-
ic metabolism in the recipient. This aspect was (ll-
ready clear to us from previous studies performed 
on the hamster-tn-rat liver xenotransplant model. Al-
though both are rodents, the phylogenetic distance 
between a hamster and a rat is put at somewhere be-
tween 15 and 40 million vears [86]. Analvsis of the 
coagulation proteins showed large differences be-
tween the two species of rodents and, when the 
hamster liver was transplanted to the r(lt, the latter's 
coagulation profile changed radically, becoming 
comparable to that of the donor anim(l1 [87]. Despite 
this, the recipient did not suffer from a hemorrhagic 
di(lthesis. Similar variations occurred in the baboon-
to-human liver xenotransplant [74, 88], where the re-
cipient acquired the same coagulation profile as the 
baboon, while ret(lining a normal prothrombin time 
and coagulation capacity [74, 88]. 
A transplanted baboon liver also continues to pro-
duce species-specific complement. This could pro-
vide immunological protection of the xenotran-
splant, since the complement produced by the ba-
boon liver should not be involved in rejection of the 
liver which produces it. The baboon liver could theo-
reticallv introduce lethal alterations into the human 
metabolic pathways, but this was not the case in this 
experience. We did see numerous changes involv-
ing, for example, the metabolism of purines, albu-
min, cholesterol and triglycerides, without this caus-
ing any deleterious effects to the host organism. 
However, all these aspects obviously require further 
detailed investigation. The metabolic issues sur-
rounding clinical xenotransplantation could well 
turn out to be a Pandora's box. 
CONCLUSIONS 
Our experience to date is still too small to allow 
conclusive scientific assertions. Only through fur-
ther work will we be able to determine the ad-
vantages and feasibility of this fascinating thera-
peutic option. However, the hope of having access to 
an unlimited number of donors is a strong incentive 
for proceeding in this direction. The Pittsburgh 
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Transplantation Institute believes that current 
knowledge of rejection immunopathology, and the 
immunosuppressant drugs at our dispos(ll, justify 
clinical trials of xenotransplantation. Starting from 
this premise we notified, in November, 1991 the Na-
tional Institute of Diabetes and Digestive and Kid-
nev Diseases of the National Institute of Health (Jav 
Hoofnagle, MD, and Philip Gordon, MO), the coo~i 
and Drug Administration (Ron Lieberman, MO, and 
Gregory Burke, MO) and the Secretary of Health and 
Human Services (Louis Sullivan, MD) that we in-
tended to proceed with the clinical liver xenotrans-
plant project. Eight months were then needed to 
present the scientific documentation in our posses-
sion to the appropriate government agencies in the 
US, our Institutional Review Board, the Ethics Com-
mittee of the University of Pittsburgh Medical Cen-
ter, and the members of the US Congress. In March, 
1992, we also brought together a committee formed 
by six eminent European and American surgeons, 
coordinated bv Keith Reemtsma of Columbia Uni-
versity, to hear the opinions of other experts before 
proceeding with the first baboon liver xenotrans-
plant. 
After making several modifications to our initial 
protocol, on the basis of suggestions made by the 
various experts consulted, we performed the first xe-
notranspIant on June 28,1992, and the second on Ja-
nuary 10, 1993. During the long interval between the 
first and the second, despite the fact that we had the 
authorization to perform 4 consecutive liver xe-
notransplants [89], we chose to bring the same 
group of experts previously consulted together 
again, this time at the New York Academy of Medi-
cine, so that thev could analvze the results obtained 
in the first xenotransplant.' On this occasion, we 
were advised to continue the clinical trial. 
A program of this kind obviously raises ethical 
problems, in addition to those of a strictly medical 
nature. Certain ethical movements consider this pro-
ject to be immoral [90]). We do not consider this the 
appropriate place to enter into the dispute between 
the supporters of interspecies equality (a modern 
equivalent of Jainism [90], supporters of species in-
equality, and "speciesists" [92]. However, we believe 
we can share the sentiments of Stephen Post [90], 
who stated that the Pittsburgh project «has success-
fully reminded us that the human good remains ap-
propriately the highest good, despite the cultural in-
roads of anthropomorphism». 
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